Drug companies are outsourcing formulation and manufacturing to specialized partners equipped with advanced hardware and AI tools to speed up development timelines for complex molecules that traditional in-house methods struggle to handle. The shift reflects a fundamental change in how the pharmaceutical industry approaches the costly, time-consuming phase between drug discovery and market approval.

Why Are Pharma Companies Outsourcing More Formulation Work?

The pharmaceutical landscape has transformed dramatically. Targeted therapies in oncology, immunology, and precision medicine have become far more sophisticated, but also far more difficult to manufacture. These new compounds often have higher potency, narrower therapeutic windows, and poor solubility, meaning they don't dissolve well in the body and require creative solutions to deliver effectively.

At the same time, artificial intelligence is accelerating drug discovery itself. Researchers can now identify promising molecules faster than ever, but this creates a bottleneck: the chemistry, manufacturing, and quality control teams can't keep pace. Contract research, development, and manufacturing organizations, or CRDMOs, have become essential partners in bridging this gap. The industry is moving away from fragmented outsourcing toward full-service CRDMO models that handle formulation, analytical development, scale-up, and regulatory readiness all under one roof.

"Outsourced formulation services are expected to evolve toward deeper integration, greater use of AI-driven development tools, and increased demand for specialized delivery technologies," said Tuneer Ghosh.

Tuneer Ghosh, Executive Vice President and Head of CMC Services, Sai Life Sciences

The trend is particularly pronounced in orphan and rare-disease drug development, where small patient populations and complex formulation challenges demand flexibility and speed. CRDMOs are now being brought in at the earliest stages, sometimes even before human testing begins, to assess whether a formulation strategy is feasible.

What Specific Challenges Are Driving This Outsourcing Boom?

Several interconnected trends are reshaping the industry. First, small molecules are no longer so small. Modern drug candidates have grown in size and complexity, often requiring multiple chemical synthesis steps and exhibiting high potency that demands careful handling and containment.

Second, solubility remains a major challenge. Many new compounds don't dissolve well in water or other solvents, which means they won't be absorbed effectively by the human body. Specialized techniques like amorphous solid dispersions, created through spray-drying processes, have become critical tools for solving this problem. According to industry experts, multiple products using these approaches have won regulatory approval.

Third, the pace of innovation is accelerating. AI is booming across the industry, enabling chemists to design and synthesize new molecules at unprecedented speed. But this creates urgency: companies need clinical supply and scaled-up manufacturing processes in much tighter timelines than the traditional drug development model allowed.

How Are CRDMOs Using Technology to Speed Development?

Contract manufacturers are deploying both hardware and software innovations to handle these challenges. On the hardware side, partnerships with equipment suppliers are enabling new manufacturing approaches. For example, continuous tableting machines that can operate in multiple modes, from small batch to commercial scale, allow chemists to develop formulations early in the process and use the same equipment later for large-scale production.

Modular continuous-flow setups are another innovation, designed with a "plug-and-produce" approach that lets chemists build manufacturing processes in a flexible, Lego-like fashion. This means the setup they develop at the bench can be scaled directly to commercial production without major redesign.

On the software side, companies are exploring sustainable chemistry approaches, including micellar chemistry, which uses less energy-intensive processes. AI-driven development tools are also becoming standard, helping teams optimize formulations faster and with fewer experiments.

How to Accelerate Drug Development Through Outsourcing

• Early CRDMO Engagement: Involve contract manufacturers at preclinical stages, not just after a molecule has been selected, to assess feasibility and define formulation strategy from the start.
• Integrated Service Selection: Choose partners offering formulation, analytical development, manufacturing scale-up, and regulatory support under one roof, rather than fragmenting work across multiple vendors.
• Specialized Expertise for Complex Modalities: Prioritize CRDMOs with proven experience in peptides, PROTACs (proteolysis targeting chimeras), gene therapies, and other advanced modalities that require specialized handling and containment.
• AI-Powered Optimization: Leverage partners who use AI-driven development tools to accelerate formulation screening and reduce the number of experiments needed to reach clinical supply.
• Long-Term Partnership Models: Move beyond transactional outsourcing relationships toward sustained partnerships that support the entire development lifecycle and can adapt as programs evolve.

What Does This Mean for Patients and Drug Timelines?

For patients, the implications are significant. Faster formulation and manufacturing timelines mean new drugs, especially those for rare diseases, can reach the market more quickly. Orphan drugs, which treat conditions affecting fewer than 200,000 people in the United States, often face compressed development timelines because patient populations are small and regulatory pathways are accelerated. CRDMOs help manage these constraints by providing flexibility, specialized expertise, and the ability to handle small-batch manufacturing efficiently.

The integration of AI into formulation development also reduces waste and experimentation. Instead of running dozens of formulation trials, AI-driven tools can predict which approaches are most likely to succeed, saving time, money, and active pharmaceutical ingredients.

Looking ahead, the pharmaceutical industry expects this outsourcing trend to deepen. Growth in personalized and precision medicine will drive demand for tailored formulation approaches, particularly for complex, low-volume programs. Companies are increasingly favoring long-term partnerships with integrated CRDMOs over transactional relationships, signaling a fundamental shift in how drug development will be organized in the coming years.